HotJobs

HotSpot Therapeutics is a clinical-stage biotechnology company pioneering a new class of allosteric medicines by targeting "natural hotspots" on proteins. These hotspots are functional pockets used by nature to control protein function, which the company identifies and targets using its proprietary Smart Allostery™ platform. The platform integrates machine learning, structural biology, and chemical biology to discover small molecules that can modulate previously undruggable or difficult-to-target proteins. Their lead program, HST-1011, is an orally bioavailable CBL-B inhibitor currently in Phase 1 clinical trials for solid tumors. The company's pipeline also includes allosteric inhibitors for high-value targets such as STAT6 and SIK2, aimed at treating autoimmune and inflammatory diseases.